Summary: Therapy of renal anaemia in haemodialysis patients with chronic renal failure by application of recombinant human erythropoietin leads to an increase of the haematocrit. Rejuvenation of the erythrocyte population results in a decrease of the median density (D 50 ), an increase of cell age-dependent enzyme activities, such as aspartate aminotransferase, and elevated concentrations of purine nucleotides in the erythrocytes. After density gradient separation of erythrocyte populations into cell age-dependent fractions, the concentrations of adenosine-S'-triphosphate, guanosine-5'-triphosphate and guanosine-5'-diphosphate were be found to be elevated by 25 -100% in all cell fractions from haemodialysis patients, compared with a healthy control group. Therapy of haemodialysis patients with recombinant human erythropoietin leads to further increase (65%) of ATP in the younger (low density) cells, but not in the older (high density) cells. The elevated concentrations of ATP and total adenine nucleotides during recombinant human erythropoietin therapy possibly result in improved deformability of erythrocytes. The data point to an enhancement of the proportion of younger erythrocytes, but not to an improvement of the reduced life span of erythrocytes of haemodialysis patients during therapy with recombinant human erythropoietin.
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The aim of this study was to answer the following questions.
1) Can the increased deformability of erythrocytes following recombinant human erythropoietin therapy, as measured in rheological studies (12, 13) , be interpreted on the basis of elevated intraerythrocytic energy-rich purine nucleotides?
2) Is recombinant human erythropoietin therapy of haemodialysis patients accompanied by an increase in the life span of erythrocytes, based on purine nucleotide measurements?
3) Do the erythrocytes of haemodialysis patients exhibit changes in purine nucleotide pattern during long term (1 year) therapy with recombinant human erythropoietin?
Patients and Methods
Eighteen healthy subjects (8 male and 10 female subjects), aged from 21 to 56 years, were compared as a control group with 14 haemodialysis patients (4 male and 10 female patients) aged from 26 to 76 years [Hb 81.5 + 5.1 g/1]. The uraemic patients were haemodialysed three times per week for 4-5 hours. The recombinant human erythropoietin dosage was chosen to produce an enhancement of haemoglobin concentrations up to 100 g/1, followed by maintenance of this value. Recombinant human erythropoietin was a gift of Boehringer Mannheim GmbH, Germany.
Blood samples (3 -5 ml venous blood) from haemodialysis patients were drawn in the morning before haemodialysis sessions. Informed consent was obtained according to standards of the Ethic Committee of the Department of Medicine of the Freie Universit t Berlin. Blood samples from control subjects were also drawn in the morning. Preparations for the different assays were immediately carried out.
Erythrocyte suspensions for density gradient centrifugation were prepared from heparinized blood. Blood (10 ml) was centrifuged for 10 min at 4 °C and 800 g. Plasma was removed and erythrocytes were resuspended in N-2-hydroxyethylpiperazine-N'-l-ethanesulphonic acid (HEPES) buffer (133 mmol/1 NaCl, 4.5 mmol/1 KC1, 10 mmol/1 HEPES, pH 7.4). The suspension was filtered through α-cellulose/microcrystalline cellulose (2 + 1, by weight) according to Beutler et al. (14) to eliminate leukocytes. The haematocrit of filtered blood was adjusted to about 0.30 with HEPES buffer (4 °C).
Percoll gradient separation (11): 2ml of filtered blood were layered on top of 12 ml of a continuous Percoll density gradient solution and centrifuged for 10 min at 10 000 g in a Sorvall centrifuge at 4 °C. The density gradient was obtained by centrifugation of a 50% Percoll solution in HEPES buffer for 10 min at 10000 g and 4 °C. Separated erythrocytes were collected from the bottom of the vials in 24 fractions (500 μΐ) using a pump and a glass capillary. Fraction 1, the highest density fraction, was located at the bottom; fraction 24, the lowest density fraction, was located at top of the vial. Densities of the fractions were determined with the help of colour markers. Each fraction was washed three times with 1000 μΐ HEPES buffer. Centrifugation was carried out hi Eppendorf vials and an Eppendorf centrifuge. Erythrocyte pellets were kept deep frozen at -20 °C until determination of enzyme activities. Samples for purine nucleotide analysis were immediately extracted.
Extraction procedure of nucleotides:
Fractions were deproteinized with ice cold 60 g/1 perchloric acid, centrifuged for 10 min at 1200 g and neutralized with K 2 CO 3 . After a second centrifugation the supernatant was stored at -20 °C. Ten or twenty microlitres of supernatant were analysed by HPLC (15, 16) . HPLC equipment of Waters Assoc., Milford, MA; USA: M510 pump, Rheodyne injector, variable wavelength detector (adjusted to 254 nm), 740 DATA Module and a 640-system controller; columns: 5 μιη Novapak C 18 cartridges (100 mm χ 8 mm i. d.) with a RCM compression system. Purine nucleotides were determined with an isocratic ion pair reversed phase HPLC system (15, 16 
Results
Erythrocytes from patients with chronic renal failure undergoing haemodialysis exhibit increased enzyme activities in all cell fractions of the Percoll gradient in comparison with erythrocytes from healthy subjects. The most prominent differences between enzyme activities of patients and healthy subjects were found in cell fractions 15 -24, which contain erythrocytes with low densities. These erythrocytes were termed young erythrocytes, as indicated by the cell age-dependent aspartate aminotransferase activity (17) (fig.  1 ). During recombinant human erythropoietin therapy, catalytic activity concentrations of aspartate aminotransferase increase, reaching a maximum one week after the start of therapy. However, these activities decrease to the initial value during the first year of therapy.
In contrast to restoration of enzyme activity after the first year of recombinant human erythropoietin therapy, median densities stay constantly low, demonstrating a continuous generation of young erythrocytes during the time of recombinant human erythropoietin administration: haemodialysis patients D 50 = 1.0548 ± 0.0002 kg/1 (p control < 0.05); haemodialysis patients after one year of recombinant human erythropoietin therapy D 50 = 1.0543 ± 0.0009 kg/1, (Pcontroi < 0.05); healthy control group D 50 = 1.0740 ± 0.0002 kg/1. Like the aspartate aminotransferase activities, the ATP concentrations in erythrocytes of haemodialysis patients are increased in comparison 
Discussion
Cell densities of erythrocytes increase with increasing cell age for nearly 120 days, the physiological life span of human erythrocytes. Therefore, the median density of the erythrocyte population has been suggested as an indicator for changes of cell age (14) . Thus, the ) and glucose-6-phosphate dehydrogenase 1 ) activities (20) .
After the first year of administration of recombinant human erythropoietin to patients, the enzyme activity decreases rapidly to values found in the cell population of patients without recombinant human erythropoietin therapy; this indicates that the toxic damage of the erythrocytes due to uraemia, persists during recombinant human erythropoietin therapy.
We found increased ATP and GTP concentrations in erythrocytes of haemodialysis patients. The increased erythrocytic ATP concentrations in uraemic patients are in agreement with previously published data (21 -24) . To our knowledge, the observation of elevated GTP concentrations, however, is a new finding. Increased ATP concentrations in uraemic erythrocytes may be due, on the one hand to a decreased loss of ATP during ageing of erythrocytes (25) and, on the other hand to changes in enzyme activities in pathways of nucleotide metabolism. Generally speaking, increases or decreases of ATP concentrations of erythrocytes reflect differences between production and consumption of this energy rich compound. In erythrocytes, generation of ATP only depends upon the flux rate through glycolysis, regulated by the enzyme activities of this pathway, especially by the activity of the key enzymes, hexokinase and phosphofructokinase. Hexokinase activity in erythrocytes is strongly cell age-dependent (17, 26) . This might be the reason for the decreased ATP concentrations in erythrocytes in dependence upon density in all three groups of patients or healthy subjects. On the other hand, the ATP consuming processes, especially transport processes through plasma membranes and processes connected with cell shape changes mediated by cytoskeleton activities, influence the topical ATP level. From a comparison between immature red blood cellsthe reticulocytes -and mature red blood cells -the erythrocytes -is known that reticulocytes exhibit a 75-fold higher rate of ATP consumption (27) and a 3-fold higher ATP concentration (28) in comparison with erythrocytes. Therefore, one may suggest that "old" erythrocytes with lower ATP content are probably characterized by a decreased ATP consumption rate under quasi steady state conditions when compared with younger cells. This may be in agreement with the disturbances of electrolyte concentrations in red cells with ageing, especially with the decrease of intracellular K+ and Mg 2 * and an increase of intracellular Na+ concentration (29) .
Increased ATP concentrations in erythrocytes of uraemic patients seem to be connected with decreased cell age; in addition, they are possibly associated with the adaptation of cells to the higher demand for the transport of electrolytes and organic compounds which are accumulated in the plasma. Furthermore, changes of enzyme activities in pathways of nucleotide metabolism in the erythrocytes of haemodialysis patients have been described by Hefti et al. (3), who showed an enhanced purine nucleotide synthesis via salvage pathways in erythrocytes of uraemic patients. The possible influence of higher phosphate concentrations on the erythrocyte glycolytic rate has also been discussed (20, 20, 31) .
The increase of the ATP concentration after the long term presence of erythropoietin can be explained as rejuvenation of the erythrocyte population. There is no doubt that in the presence of recombinant human erythropoietin the life span of red cells in haemodialysis patients remains the same (or slightly increased), compared with cells in haemodialysis patients before recombinant human erythropoietin treatment. Nevertheless, the causes of ATP enhancement in erythrocytes during recombinant human erythropoietin treatment are unknown. Tracer-kinetic experiments are necessary to obtain more information on the balance between ATP formation and consumption in erythrocytes in haemodialysis patients treated with recombinant human erythropoietin. This might answer the question of which part of ATP turnover is changed during the recombinant human erythropoietin treatment -the ATP production via glycolysis or the ATP consuming processes.
The increased ATP concentration together with increased aspartate aminotransferase activities in "old" erythrocytes from haemodialysis patients treated with recombinant human erythropoietin, compared with "old" erythrocytes before recombinant human eryth-ropoietin therapy ( fig. 1 ) may indicate an unchanged reduced life span of erythrocytes during recombinant human erythropoietin therapy. This finding is in agreement with data published in I.e. (12) . These authors measured an unchanged reduced life span of erythrocytes before and 6 months after recombinant human erythropoietin therapy.
The increased nucleotide concentrations of erythrocytes of haemodialysis patients treated with recombinant human erythropoietin can explain the partial restoration of the decreased erythrocyte deformability in haemodialysis patients (12, 13) . Several authors have clearly demonstrated the decrease of deformability of erythrocytes in patients with chronic renal failure (32) . The reasons for the beneficial recombinant human erythropoietin effect on the rheological properties of the blood (12, 13) are not yet clarified. The improved deformability of uraemic erythrocytes by the recombinant human erythropoietin therapy was explained by the assumption that during recombinant human erythropoietin therapy an increasing number of cells with normalized viscoelastic properties was formed due to stimulated erythropoiesis (13) . It is well known that the biochemical and biophysical state of the cytoskeleton, which is attached to the cytoplasmatic membrane surface, is of direct importance for the viscoelastic properties of the cell membrane, and therefore determines the deformability of the whole erythrocyte. It was mentioned above that several authors have related the reduced deformability of uraemic erythrocytes to a permanent oxidative stress caused by so called uraemic toxins in the blood plasma (7) . If the impaired deformability is primarily caused by the action of uraemic toxins, one would expect that the erythrocytes formed under the recombinant human erythropoietin therapy would also possess this feature. But the findings of Meier et al. (13) underline the fact that the impaired deformability of erythrocytes from haemodialysed patients cannot be attributed alone to an action of "uraemic toxins" during ageing of erythrocytes in the blood circulation. On the basis of the results presented here we propose that the further increase of the intraerythrocytic concentrations of energy-rich adenosine nucleotides, especially ATP and AMP, within the younger cell fractions, and ADP and AMP in the older cell fractions, during recombinant human erythropoietin therapy, is responsible for the improvement of rheological properties of the blood of patients with chronic renal failure. Thus, the results of our study point to an increase of haemocrit with an enhancement of the proportion of younger erythrocytes, but not to an improvement of the reduced life span of erythrocytes of haemodialysis patients during recombinant human erythropoietin therapy.
